ENTX · Entera Bio Ltd. · Executive Compensation
$2.84
-0.02 (-0.70%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 7, 2026
The latest filing states the doubt was alleviated.
“Following the closing of the private placement and receipt of the related net proceeds, management concluded that substantial doubt about the Company’s ability to continue as a going concern no longer exists.”View the 10-Q filed Aug 7, 2026
Market Cap
$453.63M
Shares
173.14M
Volume · Oct 5
1.25M
Avg daily vol (3M)
1.8M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Miranda Toledano | Chief Executive Officer and director | $1,149 |
| Dana Yaacov-Garbeli | Chief Finance Officer | $438 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Miranda Toledano | Chief Executive Officer and director | $950 |
| Hillel Galitzer | Chief Operating Officer | $459 |
| Dana Yaacov-Garbeli | Chief Finance Officer | $311 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Dr. Phillip Schwartz | Former President of R&D | $782 |
| Miranda Toledano | Chief Executive Officer and director | $679 |
| Hillel Galitzer | Chief Operating Officer | $621 |
| Dr. Hillel Galitzer | Chief Operating Officer | $621 |
| Dana Yaacov-Garbeli | Chief Finance Officer | $381 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Spiros Jamas | Former Chief Executive Officer | $1,143 |
| Dr. Phillip Schwartz | Former President of R&D | $685 |
| Dr. Hillel Galitzer | Chief Operating Officer | $640 |
| Miranda Toledano | Chief Executive Officer and director | $82 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Dr. Phillip Schwartz | Former President of R&D | $610 |
| Dr. Hillel Galitzer | Chief Operating Officer | $527 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Geno H. Germano | Class III director | Appointed | 2026-07-16 |
| Steven D. Rubin | Class III director | Appointed | 2026-07-16 |
| Sean Ellis | Class III director | Appointed | 2026-07-16 |
| Gerald Lieberman | Director | Resigned | 2026-02-09 |
| Geno J. Germano | Class III director | Appointed | 2026-02-09 |
| Gerald Lieberman | Chairman of the Board | Resigned | 2026-02-09 |
| Geno J. Germano | Chairman of the Board | Appointed | 2026-02-09 |
| Steven D. Rubin | Class III director | Appointed | 2026-02-04 |
| Gerald Ostrov | Director | Resigned | 2026-02-04 |
| Haya Taitel | director | Appointed | 2023-06-07 |
| Spiros Jamas | officer as well as a member of any board of directors, and any committee thereto, throughout the Company Group | Resigned | 2022-07-18 |
| Spiros Jamas | Chief Executive Officer | Resigned | 2022-07-18 |
| Dana Yaacov-Garbeli | Chief Financial Officer (principal financial officer) | Appointed | 2022-07-18 |
| Miranda J. Toledano | Chief Financial Officer (principal financial officer) | Resigned | 2022-07-18 |
| Miranda J. Toledano | Chief Executive Officer (principal executive officer) | Appointed | 2022-07-18 |